Insulet Corporation · NASDAQ:PODD
Insulet — Investor Presentation (May 2023)
20 slides from Insulet's investor presentation, May 2023
Slide 1: Insulet Corporation Investor Presentation May 2023
Insulet Corporation Investor Presentation May 2023 Christian D Podder since 2020 1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments a
Slide 3: Today's Agenda
Today’s Agenda 1 Capturing the Large and Underpenetrated Market 2 Realizing the Omnipod 5 Opportunity 3 Penetrating and Leading in the Type 2 Diabetes Market 4 Powering Mission with Strong Financial Profile Giuliana P Podder since 2016 3
Slide 4: Our Mission and How We Achieve It
Our Mission and How We Achieve It Simplify life for people with diabetes • Omnipod platform • Reduce burden • Improve outcomes Market-leading technology Market-leading revenue growth Competitive Advantages Long-term value creation • Talent • Innovation • Scalable operations • Data infrastructure Jad
Slide 5: Delivering Results while Expanding our Portfolio
Delivering Results while Expanding our Portfolio Total 2022 Omnipod revenue growth of 27%1 More than doubled intellectual property portfolio over the last year 7th consecutive year of 20% or more revenue growth1 in 2022 One of America’s most responsible companies, as recognized by Newsweek4 Q1’23 U.
Slide 6: Massive Market Opportunity
Massive Market Opportunity Current Total Addressable Market 537M+ ~11M People 2 People with Diabetes Worldwide1 ~64M ~45% ~55% Requiring Insulin Worldwide1 Type 1 Insulin-Intensive Type 2 2024 ~14M With U.S. Omnipod GO Morgan M Podder since 2009 1. Source: IDF Atlas 10th Edition. 2. Comprised of ~1.
Slide 7: Omnipod Is Unlocking the Largest Market Opportunity
Omnipod Is Unlocking the Largest Market Opportunity Conventional Insulin Pump Multiple Daily Injections (MDI) ~5% ~95% of the global market opportunity1 of the global market opportunity1 Alecia B Podder since 2017 vs. vs. One Pod replaces approximately 14 injections 7 1. Percentage of global insulin
Slide 8: Omnipod 5 Wins on All Dimensions
Omnipod 5 Wins on All Dimensions The Obvious OMNIPOD PLATFORM + OMNIPOD 5 WITH AID = Choice • No needles or tubes • Novel algorithm using micro-dose technology • Discreet, wearable, disposable • Industry-leading time in range • Pay-as-you-go economics for customers and payors • Very few hypoglycemic
Slide 9: Omnipod 5 Delivers Exciting Clinical Outcomes
Omnipod 5 Delivers Exciting Clinical Outcomes Time in TIR Time in Age Group range (TIR) improvement closed loop 14-70 yrs1 73.9% 9.3% 96.7% 6-13 yrs1 68.0% 15.6% 96.4% 2-5 yrs2 68.1% 10.9% 97.8% Strong performance in the pivotal trials Note: First release of real-world evidence for Omnipod 5 present
Slide 10: Building a Full Range of Options for Type 2
Building a Full Range of Options for Type 2 Patient Journey Diet & Exercise Oral Medications Basal Insulins Basal-Bolus Insulins Omnipod DASH Improved glycemic management and reduction in insulin usage Omnipod GO No needles, ease of Omnipod 5 adoption and expected All the benefits of improved adhere
Slide 11: Innovation Drives Horizons of Growth
Innovation Drives Horizons of Growth Value 537M+ People with Diabetes Worldwide1 Lead the Industry with ~64M Requiring Insulin Novel Innovations Worldwide1 Expand TAM • Next-generation algorithms Drive Omnipod 5 Growth • Next-generation hardware • AI / machine learning-based data • Omnipod GO and Om
Slide 12: Leveraging our Manufacturing Capabilities
Leveraging our Manufacturing Capabilities • Creating Supply Chain Redundancy – Regionally diverse manufacturing • Expanding Global Capacity – New Malaysia facility under construction • Building Talent and Capabilities – 20+ years of Pod engineering experience Insulet U.S. Manufacturing 12
Slide 13: Strong Financial Profile Powering the Mission
Strong Financial Profile Powering the Mission Maximizing Investing Expanding Revenue for Growth Operating Margins ~23% ~19% +~11pts Revenue CAGR R&D Expense CAGR Adjusted Operating Margin 2018 - 20231 2017 - 2022 2017 - 20222 1. 2023 reported high-end revenue guidance as provided on the Q1’23 earnin
Slide 14: Incredible 2022 ESG progress
Incredible 2022 ESG progress Launched Product Takeback pilot 67% of our current Board of in U.S. to explore shift to a more Directors are gender and/or circular business model ethnically diverse Received ‘AA’ MSCI Environmental, Social, and Governance (ESG) rating Generated 900+ MWh Obtained additio
Slide 15: Positioned for Continued Success
Positioned for Continued Success 1 Capturing the Large and Underpenetrated Market 2 Realizing the Omnipod 5 Opportunity 3 Penetrating and Leading in the Type 2 Diabetes Market 4 Powering Mission with Strong Financial Profile Ernesto M Podder since 2017 15
Slide 16: Thank You
Thank You Grant H Podder since 2022 16
Slide 17: Appendix
Appendix Insulet
Slide 18: Reconciliation of Non-GAAP Measures Revenue
Reconciliation of Non-GAAP Measures Revenue Quarter Ended March 31, 2023 2022 Percent Change Currency Impact Constant Currency U.S. Omnipod $259.0 174.1 48.8% -% 48.8% International Omnipod 98.6 95.4 3.4% (6.2)% 9.6% Total Omnipod 357.6 269.5 32.7% (2.2)% 34.9% Drug Delivery 0.5 25.9 (98.1)% -% (98.
Slide 19: Reconciliation of Non-GAAP Measures Revenue (continued)
Reconciliation of Non-GAAP Measures Revenue (continued) Year Ended December 31, 2022 2021 Percent Change Currency Impact Constant Currency U.S. Omnipod $884.8 651.5 35.8% -% 35.8% International Omnipod 363.0 359.9 0.9% (11.2)% 12.1% Total Omnipod 1,247.8 1,011.4 23.4% (4.0)% 27.4% Drug Delivery 57.5
Slide 20: Reconciliation of Non-GAAP Measures Operating Margin
Reconciliation of Non-GAAP Measures Operating Margin Year Ended December 31, 2022 (dollars in millions) Operating Income Revenue Percent of Revenue GAAP $37.6 $1,305.3 2.9% Voluntary medical device corrections1 57.9 Legal costs2 25.2 CEO transition costs3 3.4 Non-GAAP $124.1 $1,305.3 9.5% The Compan